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Abstract 
Darier disease (DD) is an autosomal dominant skin disorder caused by mutations in ATP2A2 encoding the 
sarco/endoplasmic reticulum Ca2+ ATPase Isoform 2 (SERCA2). Evidence of a population-level association 
between DD and psychiatric disorders suggests that mutations in ATP2A2 may have pleiotropic effects on the 
brain as well as skin. Evidence of genotype–phenotype relationships between ATP2A2 mutations and 
neuropsychiatric phenotypes would further support this suggestion. We investigated genotype–phenotype 
correlations between lifetime neuropsychiatric features and ATP2A2 mutation type (dichotomized into likely 
gene disrupting [LGD] or protein altering) in 75 unrelated individuals with DD. We also looked for evidence of 
clustering of mutations within SERCA2 according to neuropsychiatric features. Combining our data with the 
existing literature, the rate of LGD mutations was found to be significantly higher among DD cases/families 
with bipolar disorder, schizophrenia, or affective psychosis (p = .011). We also found a significant relationship 
between mutations located in the S4– M4 region of the protein and the presence of a severe neuropsychiatric 
phenotype (p = .032). Our findings add support to the hypothesis that Darier-causing mutations in ATP2A2 
confer susceptibility to neuropsychiatric dysfunction, in particular severe psychiatric illness. This, together with 
evidence from research on common polymorphisms confirms ATP2A2 as a gene at which variation influences 
susceptibility to major psychiatric illness. 
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1 | INTRODUCTION 
Darier disease (DD) is a rare autosomal dominant inherited skin disorder with an estimated average prevalence 
of between 1 in 100,000 and 30,000 (Svendsen & Albrectsen, 1959; Tavadia, Mortimer, & Munro, 2002) and 
usually presents in the second decade with no sex difference (Burge & Wilkinson, 1992). It is characterized by 
hyperkeratotic papules in seborrheic areas, palmo-plantar pits, and nail dystrophy. DD is inherited with a high 
penetrance although the phenotypic expression is variable (Munro, 1992). 
 
The disease is caused by mutations in the gene ATP2A2 (Sakuntabhai, Ruiz-Perez, et al., 1999) which encodes 
the sarco/endoplasmic reticulum (ER) Ca2+ ATPase Isoform 2 (SERCA2), a calcium pump located in the ER 
membrane which plays a key role in Ca2+ homeostasis. The protein contains five major domains which include 
11 transmembrane helices (M1–M11), 5 stalks (S1–S5), and 3 cytoplasmic domains: the actuator (A) domain, 
the nucleotide ATP-binding (N) domain, and the phosphorylation (P) domain. To date, well over 
200 different Darier-causing mutations have been identified throughout ATP2A2 including missense, nonsense, 
substitutions, and both frame-shift and in-frame insertions and deletions (Human Gene Mutation Database 
http://www.hgmd.org). Generally, these mutations do not seem to cluster within potential “hot-spot” regions 
throughout the primary sequence of the SERCAb molecule and most are unique within individual families. 
 
The co-occurrence of neuropsychiatric features, including depression, bipolar disorder, epilepsy, and learning 
difficulties, with DD has frequently been reported (Burge & Wilkinson, 1992; Cederlöf et al., 2015; Cederlöf et 
al., 2015; Denicoff, Lehman, Rubinow, Schmidt, & Peck, 1990; Dodiuk-Gad et al., 2014, 2016; Gordon-Smith et 
al., 2010; Medansky & Woloshin, 1961; Ringpfeil et al., 2001). The nature of this co-occurrence has long been 
debated in the literature with a number of potential explanations being put forward. A seemingly plausible 
explanation is that the high psychiatric morbidity observed in DD is a direct psychological consequence of 
having a chronic skin disorder. However, our previous investigations into the neuropsychiatric phenotype in 
DD and the work of others have not found any significant relationships between psychiatric phenotypes and 
DD clinical features including disease severity, suggesting this argument alone cannot account for the 
association (Dodiuk-Gad et al., 2016; Gordon-Smith et al., 2010). 
 
In recent years, studies have found evidence of a population-level association between DD and psychiatric 
disorders—specifically mood disorders, including bipolar disorder, and schizophrenia (Cederlöf, Bergen, et al., 
2015; Dodiuk-Gad et al., 2016; Gordon-Smith et al., 2010). This included a matched cohort study based on 
Swedish national registers that found individuals with DD had a 4.3 and 2.3 times higher risk of bipolar 
disorder and schizophrenia, respectively, than individuals in the general population (Cederlöf, Bergen, et al., 
2015). These findings suggest that mutations in ATP2A2 have pleiotropic effects in the skin and brain and 
confer susceptibility to neuropsychiatric features. This theory would be strongly supported by evidence of 
genotype–phenotype relationships between ATP2A2 mutation type and co-occurrence of neuropsychiatric 
phenotypes. 
 
To date, a small number of studies have examined genotype– phenotype correlations with the 
neuropsychiatric phenotypes observed in DD (Bchetnia et al., 2009; Dodiuk-Gad et al., 2016; Jacobsen et al., 
1999; Nellen et al., 2016; Ringpfeil et al., 2001; Ruiz- Perez et al., 1999; Sakuntabhai, Burge, Monk, & 
Hovnanian, 1999) with no clear and consistent correlations being identified. Difficulties in establishing these 
relationships may be because of a number of reasons including small sample sizes (ranging from 8 to 49 cases) 
and the use of diverse methods to measure neuropsychiatric phenotypes. The lack of consistent application of 
any standardized method of grouping the types of mutations has also been a major methodological 
impediment. A recent review of the literature divided reported Dariercausing mutations into two categories: 
(a) likely gene disrupting (LGD) mutations (frameshift, splice site, nonsense, gain of stop codon, or loss of start 
codon) and (b) protein altering (PA) mutations (missense or inframe-insertion/deletions; Nakamura et al., 
2016). This study found significantly higher rates of LGD mutations in Darier cases with reported co-occurring 
neuropsychiatric features than in those without such features. A single study has reported a nonrandom 
clustering of mutations in the last half of ATP2A2 and a neuropsychiatric phenotype (in a sample of 19 
unrelated individuals with DD; Jacobsen et al., 1999). However, no other genotype–phenotype associations 
between mutation location along the primary structure of the gene and the presence of neuropsychiatric 
features have been reported in other samples (Dodiuk-Gad et al., 2016; Nellen et al., 2016; Ringpfeil et al., 
2001) including the recent literature survey (Nakamura et al., 2016). The authors of the survey noted that this 
lack of association would be reasonable as LGD mutations in any exon could result in similar molecular 
consequences. 
 
We have previously reported a systematic investigation of the neuropsychiatric characteristics in a large U.K. 
sample of unrelated individuals with DD (Gordon-Smith et al., 2010), and more recently reported the disease 
causing sequence variants of ATP2A2 within this large sample (Green et al., 2013). Although these mutations 
were included in the recent analysis by Nakamura et al. (2016), the associated neuropsychiatric phenotypes 
were unknown to the authors at the time. In the current study, we investigated potential correlations between 
mutation type (LGD vs. PA) and neuropsychiatric phenotypes among 75 unrelated individuals with DD. This is 
the largest such study to date. This large sample has also enabled us to look for evidence of clustering of 
mutations within the SERCA2 protein among individuals with similar neuropsychiatric phenotypes and we 
report that here. Using this clustering approach may be a more useful way of examining genotype–phenotype 
correlations with neuropsychiatric phenotypes in DD given the likely complex nature of the associations. 
Finally, we combined our sample with previously reported DD cases/families in the literature to date to 
establish whether any genotype–phenotype correlations observed were enriched in the combined dataset. 
 
2 | MATERIALS AND METHODS 
 
2.1 | Recruitment of participants 
 
A detailed description of the sample has previously been published (Gordon-Smith et al., 2010). In summary, 
100 unrelated individuals with a diagnosis of DD were recruited throughout the United Kingdom mainly via 
dermatology services and the U.K. Darier Support Group. The study was approved by the Multi-Centre 
Research Ethics Committee for Wales. 
 
2.2 | Neuropsychiatric assessment 
 
Neuropsychiatric assessments were conducted in a single session by a trained research psychologist (KGS). 
Psychiatric symptomatology, including history of suicidal thoughts/attempts, was measured using an adapted 
version of Schedules for Clinical Assessment in Neuropsychiatry interview (Wing et al., 1990). This information 
was supplemented by psychiatric notes and/or general practice case-notes. Lifetimeever psychiatric diagnoses 
were made according to the Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV; 
American Psychiatric Association, 2000). Three experienced research psychologists/ psychiatrists (KGS, LJ, and 
NC) made the psychiatric ratings independently, using written case vignettes, and consensus was reached. 
Inter-rater reliability was high with mean kappa statistics of 0.86 and 0.93 for DSM-IV diagnoses and suicidal 
ideation, respectively. Lifetime history of neurological symptoms and disorders was assessed using a brief 
interview checklist, supplemented by hospital and/or general practice case-notes. 
 
2.3 | ATP2A2 variant identification 
 
A DNA sample was obtained from 95 individuals. Sixty-six potentially pathogenic mutations in ATP2A2 were 
identified in 74 individuals. No potentially pathogenic variant in ATP2A2 was identified in the remaining 
21 individuals. One of the five remaining individuals from whom a sample was not collected had taken part in a 
previous study (Sakuntabhai, Ruiz-Perez, et al., 1999) from which the potential pathogenic variant was 
supplied. For further details on the identification of mutations, see our previous publication (Green et al., 
2013). 
 
2.4 | Genotype–phenotype correlations 
 
According to the definitions used in a recent study (Nakamura et al., 2016), mutations were classified as either 
LGD (frameshift insertions/ deletions, mutations predicted to alter a splice codon, nonsense mutations, gain of 
stop codon, or loss of start codon) or PA (missense or inframe-insertion/deletions). 
 
Rates of LGD and PA mutations were compared between individuals stratified according to the presence or 
absence of each of the following key lifetime neuropsychiatric features:  
 
1. Any neuropsychiatric phenotype. 
2. Any psychiatric disorder meeting DSM-IV criteria. 
3. Contact with a neurologist or neurological procedure. 
4. Suicide attempt. 
5. Severe neuropsychiatric phenotype (bipolar disorder, schizophrenia, or affective psychosis). 
 
All mutations detected were mapped onto a schematic diagram of the SERCA2b protein to look for evidence of 
possible clustering of mutations according to occurrence within individuals of similar neuropsychiatric 
features. 
 
2.5 | Combined analysis with existing literature 
 
We combined our sample with the previously reported DD cases/families in the literature with an identified 
Darier causing mutation (n = 384 including the current sample).  
Within the combined sample, we 
 
1. Compared rates of LGD and PA mutations according to the absence or presence of a reported severe 
neuropsychiatric phenotype. 
2. Compared the rates of mutations located in specific functional domains of the SERCA2 protein according to 
the absence or presence of a reported severe neuropsychiatric phenotype. 
 
A severe neuropsychiatric phenotype was rated as present if the index case and/or a family member with DD 
was reported as having a diagnosis of bipolar disorder, schizophrenia, or affective psychosis. All members of 
the same family will have the same DD causing mutation and therefore a shared diathesis. Within this analysis, 
we also included an unpublished missense mutation (P312R) identified in an individual with DD and bipolar 
disorder seen by our research group as part of our ongoing mood disorders research program who was not 
included in the current study as they were identified on the basis of having bipolar disorder rather than on the 
basis of having DD. 
 
 
2.6 | Statistical analyses 
 
Groups were compared using Chi-Square Tests or Fisher’s Exact Tests where 20% or more of the cells in a Chi-
square table had an expected count of <5. For significant findings (p < .05), odds ratios with 95% confidence 
intervals (95% CI) were calculated. Statistical analyses were carried out using Statistical Package for the Social 
Sciences (SPSS) for Windows. 
 
3 | RESULTS 
 
3.1 | Current sample (75 cases) 
 
Table 1 summarizes the DD clinical and neuropsychiatric features in the sample along with the type and 
location of ATP2A2 mutation identified and mutation classification according to the LGD and PA groupings. 
 
In our 75 cases, we found a consistent nonsignificant trend for a higher prevalence of LGD mutations among 
individuals with a lifetime occurrence of each of the neuropsychiatric phenotypes compared with individuals 
with the absence of the neuropsychiatric phenotype (any neuropsychiatric phenotype 45.5% vs. 35%, p = .418; 
any psychiatric disorder meeting DSM-IV criteria 46% vs. 38%, p = .480; contact with a neurologist or 
neurological procedure 53% vs. 36%, p = .127; suicide attempt 50% vs. 41%, p = .733; severe neuropsychiatric 
phenotype 75% vs. 41%, p = .307; Figure 1; Table 2). 
 
We observed possible clustering of mutations according to individuals with similar neuropsychiatric 
phenotypes (Figure 2), but none reached statistical significance: 
 
1. All four individuals with mutations located in the functional “A” domain between the Stalk 2 and Stalk 3 
domains of the protein had a history of a psychiatric disorder severe enough to warrant contact with 
psychiatric services (IDs 11, 12, 13, and 14). 
2. Three individuals with the same missense mutation at one of the seven Ca2+ binding sites in the M5 domain 
all had a DSM-IV diagnosis of a mood disorder (IDs 54, 55, and 56). 
3. Two individuals with frameshift mutations one base pair apart in the S4 (Stalk 4) domain of the protein both 
had a history of suicide attempts in addition to having idiopathic epilepsy (ID 19) and an extensive psychiatric 
history including major depressive disorder and investigations for a blackout (ID 20). 
 
3.2 | Analysis of combined data with existing literature (384 cases) 
  
In the combined analysis with existing literature, the rate of LGD mutations was significantly higher where a 
history of a severe neuropsychiatric phenotype (bipolar disorder, schizophrenia, or affective psychosis) was 
reported in either the index case and/or family member with DD compared those without a reported history; 
68% versus 40.5%, p = .011 (OR 3.15, 95% CI 1.25–7.91; Table 3). This remained significant when we only 
included the 14 cases of bipolar disorder; 71.4% versus 41.0%, p = .024 (OR 3.44, 95% CI 1.10–10.76). With 
respect to mutation location, no significant genotype–phenotype correlations were found with mutations 
located in the “A” domain of the SERCA2 protein or calcium binding sites. However, the rate of mutations 
located between the Stalk 4 and transmembrane Helix 4 (S4– M4) region was significantly higher where a 
history of a severe neuropsychiatric phenotype was reported compared to where not; 14% versus 3%, Fisher’s 
= 0.032 (OR 5.66, 95% CI 1.41–21.88). When this analysis was narrowed down further to only include PA, 
mutations became more significant: 43% versus 4%, Fisher’s = 0.003 (OR 19.22, 95% CI 3.67–100.6). A 
summary of all mutations identified by our research group and those in the literature located within the 
S4–M4 region is presented in Figure 3 along with brief descriptions of all known neuropsychiatric features 
reported among individuals/ families with DD the mutations. This includes two families with bipolar disorder 
and an individual with schizophrenia (Figure 3). 
 
 
 
 
 
4 | DISCUSSION 
 
Our genotype–phenotype investigations have been carried out in the largest sample of individuals with DD to 
date. Consistent with there cent prior report (Nakamura et al., 2016), we found that LGD mutations were 
relatively more common in those DD individuals with neuropsychiatric phenotypes than those without such 
phenotypes. We had only four cases in our sample that met the prior report’s definition of “psychosis” (bipolar 
disorder, schizophrenia, and affective psychosis). Of these four cases, three had LGD mutations and one had a 
PA mutation. Because of the small numbers, this difference compared to those with DD without “psychosis” 
does not meet statistical significance. However, when we add our new data to the existing literature, the 
statistical significance of the finding that the rate of LGD mutations is higher among cases/families with this 
severely defined neuropsychiatric phenotype is strengthened (p = .011, compared with the previously reported 
p = .026 [Nakamura et al., 2016] which although, included our cases the neuropsychiatric features associated 
with the mutations were unknown to the authors), and this association remains significant even when the 
phenotype definition is narrowed to include only bipolar disorder. We also observed in our sample that 
mutations in individuals with similar neuropsychiatric phenotypes tended to cluster in certain locations within 
the SERCA2 protein but none reached statistical significance. In our combined analysis, we did however find a 
significant relationship with mutations located in the S4–M4 region of the protein and the presence of a severe 
neuropsychiatric phenotype. Furthermore, when this analysis was repeated with only PA mutations the 
association remained significant. This finding has not previously been reported. 
 
 
 
 
 
 
It is highly plausible that mutations in ATP2A2 could be involved in conferring susceptibility to neuropsychiatric 
illness because the gene is widely expressed in the brain. The dual role of the SERCA2b protein in intracellular 
Ca2+ signaling and in the synthesis and posttranslational modification of proteins within the ER also provides 
support for this suggestion. Intracellular Ca2+ signaling has been shown to play a role in a range of neuronal 
functions including neuronal excitability, neurotransmitter release, gene expression, neuronal growth, and 
synaptic plasticity (Berridge, 2002; Berridge, Bootman, & Lipp, 1998; Verkhratsky, 2005). Genome-wide 
association studies (GWAS) have suggested the role of calcium signaling and calcium-channel activity in the 
pathogenesis of a number of major psychiatric disorders, including bipolar disorder and schizophrenia (Cross-
Disorder Group of the Psychiatric Genomics Consortium & Genetic Risk Outcome of Psychosis (GROUP) 
Consortium, 2013; Ferreira et al., 2008) with a more recent GWAS identifying ATP2A2 as a schizophrenia 
associated loci (Ripke et al., 2014). 
 
 
  
 
A recent study showing Darier keratinocytes display the hallmarks of constitutive ER stress with increased 
sensitivity to ER stressors lead the authors of the study to suggest DD should be classed as an ER stress related 
disease (Savignac, Simon, Edir, Guibbal, & Hovnanian, 2014). There is also evidence for the role of ER stress 
responses in neuropsychiatric disorders. Lymphoblastoid cell lines from individuals with bipolar disorder have 
showed an impaired response to ER stress (Hayashi et al., 2009; Pfaffenseller et al., 2014; So, Warsh, & Li, 
2007). 
Lithium is the main mood stabilizer used in the treatment of bipolar disorder and a recent study identified the 
response to ER stress as a lithium-regulated gene network (Breen et al., 2016). It is possible that the function 
of SERCA2b pumps may be more critical in the skin and the brain than in other tissues. Both tissues may have a 
particular susceptibility to a reduction in SERCA2b activity possibly relating to changes in ER Ca2+ 
concentration and ER functioning. 
 
A limitation of the current analysis is that despite being the largest study to date, the small stratified group 
sizes in our genotype– phenotype analyses limits the power to detect significant relationships. Combining our 
sample with the existing literature enabled us to address this. However, previous studies of DD cases/families 
in the literature have not all recorded and/or reported neuropsychiatric features. Similarly, where 
neuropsychiatric features have been reported previously in the literature, in many cases only brief descriptions 
are provided. Ours and other studies have not included detailed assessments of the presence of neurological 
features such as hearing difficulties. Further studies systematically assessing neuropsychiatric features in 
individuals with DD are warranted including the administration of specific neurological tests such as 
audiograms. 
 
We have found evidence to support the suggestion that mutations in ATP2A2 in addition to causing DD, confer 
susceptibility to neuropsychiatric features in individuals with DD. Given the complex nature of the disorders it 
is likely that the pleiotropic effects occur in association with other modifying factors. Our findings suggest that 
DD causing mutations as well as other genes encoding proteins in the same biological system as, and/or 
encoding proteins with a similar function to, SERCA2b would be good candidates for further investigations of 
potential involvement in predisposing individuals to developing severe neuropsychiatric illness. 
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